← Back to Tech · Lead story
AlphaGenome 2 key art: glowing pink translucent cubes on a dark purple background beside the DeepMind logo and title

Google DeepMind’s AlphaGenome 2 predicts how DNA changes play out in specific cell types

Not every AI launch is a chatbot. Google DeepMind announced AlphaGenome 2 on Wednesday, November 11, a model that predicts how changes in DNA affect specific human cell types, from heart muscle to immune cells (Google DeepMind).

What’s new

  • Cell-level focus: the first AlphaGenome looked at broad tissue averages; version 2 predicts effects one cell type or state at a time.
  • Trained big: more than 100 million individual cell profiles across 68 tissues, per DeepMind.
  • DeepMind’s numbers: on one immune-cell benchmark it found nearly twice as many causal variants as the original (30% vs. 16%). Those are the company’s own figures.
  • New cells, no retraining: scientists can feed in data from a few dozen cells to study states the model hasn’t seen, like vaccine-activated T cells.

Who can use it

It’s available now for non-commercial research through the AlphaGenome API, and in private preview for commercial research. DeepMind is clear that it’s for research only and not approved for clinical or diagnostic use.

Koffee take: the quiet science models are often the ones that matter most a decade from now.

Filed Nov 12, 2026 ~8:30 PM CT — Evening pass. Sources: Google DeepMind (Nov 11, 2026). Card image: official AlphaGenome 2 art.